CELLSOURCE CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,522 JPY | +0.33% |
|
+3.75% | +19.00% |
| 2023 | Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023. | CI |
| 2023 | MEDERI Inc. announced that it has received funding from CellSource Co., Ltd. | CI |
ETFs positioned on CellSource Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.09% | 24 M€ | -14.52% | ||
| 0.28% | 23 M€ | +1.75% | - | |
| 0.02% | 2 M€ | -.--% |
CellSource Co., Ltd. is a Japan-based company engaged in regenerative medicine related business and consumer business. The Company operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
Calendar
2024-06-09
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.00% | 191M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- 4880 Stock
- Funds and ETFs CellSource Co., Ltd.
